Position in SCYX
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$201,005
New position
Shares Held
49,387
first reported quarter
Ownership
0.496%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#17
of 39 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026ADAR1 Capital Management, LLC holds $25,810,127 across 10 Drug Manufacturers - Specialty & Generic names. SCYX ranks #10 (0.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TEVA |
Teva Pharmaceutical Industries Ltd
|
277,848 | $9,413,490 | |
| 2 | AMLX |
Amylyx Pharmaceuticals, Inc.
|
494,378 | $8,879,028 | |
| 3 | KNSA |
Kiniksa Pharmaceuticals International, plc
|
26,913 | $1,721,086 | |
| 4 | BCRX |
Biocryst Pharmaceuticals Inc
|
133,000 | $1,330,000 | |
| 5 | SUPN |
Supernus Pharmaceuticals, Inc.
|
27,842 | $1,294,931 | |
| 6 | INM |
InMed Pharmaceuticals Inc.
|
800,000 | $1,240,000 | |
| 7 | TXMD |
TherapeuticsMD, Inc.
|
342,447 | $756,807 | |
| 8 | EOLS |
Evolus, Inc.
|
100,000 | $694,000 |
All Filings in SCYX
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $201,005 | 49,387 | Shares | Sole | 2026-08-14 | |
| No filing history on record for this holder in this stock. | ||||||